REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy?

REGENXBIO Inc. (NASDAQ:RGNX) shares gapped up before the market opened on Monday . The stock had previously closed at $14.59, but opened at $15.47. REGENXBIO shares last traded at $15.3530, with a volume of 196,088 shares changing hands.

Analysts Set New Price Targets

A number of analysts have commented on RGNX shares. Wall Street Zen raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Monday, November 24th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Thursday, November 20th. Stifel Nicolaus increased their price target on shares of REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of REGENXBIO in a report on Tuesday, October 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

REGENXBIO Price Performance

The stock has a fifty day simple moving average of $13.02 and a 200-day simple moving average of $10.81. The company has a market capitalization of $774.79 million, a price-to-earnings ratio of -4.40 and a beta of 1.07.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.18. The firm had revenue of $29.73 million during the quarter, compared to analysts’ expectations of $24.41 million. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. As a group, equities analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Hedge Funds Weigh In On REGENXBIO

Several institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC boosted its position in REGENXBIO by 52.4% during the fourth quarter. SG Americas Securities LLC now owns 40,531 shares of the biotechnology company’s stock worth $584,000 after purchasing an additional 13,931 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of REGENXBIO by 64.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock worth $16,709,000 after buying an additional 454,977 shares during the period. Diversified Trust Co. lifted its position in shares of REGENXBIO by 24.3% during the 4th quarter. Diversified Trust Co. now owns 13,378 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,615 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in REGENXBIO by 13.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 44,429 shares of the biotechnology company’s stock valued at $630,000 after acquiring an additional 5,115 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in REGENXBIO by 4.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock worth $38,959,000 after acquiring an additional 185,223 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.